Marker Therapeutics, Inc. MRKR
Marker Therapeutics, Inc. (Nasdaq: MRKR) is an oncology drug developer. Its lead program, MT-601, is in Phase 1 for Relapsed lymphoma (post anti-CD19 CAR-T or ineligible). Its next catalyst on record is MT-601: Commence larger pivotal trial in lymphoma (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: MT-601 — Commence larger pivotal trial in lymphoma (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| MT-601 | Relapsed/refractory lymphoma (APOLLO) | cell therapy | Pivotal lymphoma trial planned to start 2026 |
| MT-601 | Pancreatic cancer | cell therapy | — |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.